Global Summit on Skincare and Plastic Aesthetic - 4 minutes read

Skin care conference

3rd Global Summit on Skincare and Plastic Aesthetic

On November 20-21, 2023 the 3rd Global Summit on Skincare and Plastic Aesthetic will be held in Bangkok, Thailand. This Skincare conference will draw lecturers, academics, and renowned speakers from all around the world. The conference Theme is "Progression in skincare and Plastic Aesthetics.


Cosmetology is the branch of study and use of hair styling, skincare, cosmetics, nail clippers/pedicures, non-permanent hair extensions, and ultrapermanent hair removal measures. Estheticians are prepared and authorized to administer restorative medical treatments to hair, skin, and nails. They can also provide different services such as shading, replenishing, perming, and restoring. Estheticians help their clients enhance or achieve a specific look by applying pre-workout aesthetic applications.

Plastic surgeries

Plastic surgery is a medical procedure aimed at managing reproduction or modifying the human body. It is divided into two types of medical acts: reconstructive and aesthetic medical acts. Reconstructive medical procedures are those performed on deformities due to birth, injury, and waste, and also include the treatment of malignant skin tumors. Restorative medical procedures are used to enhance or improve appearance.

Our Organizing Committee

Clemens Escheis a visiting professor of dermatology, professor of skin care and at the Beautiful Skin Institute in Northern Virginia, USA, Russia, and Adolfo Napolez is also a professor at the University of Manchester Adolfo Napolez M.D. graduated from Southern Illinois University School of Medicine followed by a General Surgery Residency at West Penn Hospital in Pittsburgh, Pennsylvania, and followed that up with a Burn Surgery Chief Residency at Cook County Hospital in Chicago, Illinois and finally a two-year Fellowship in General Cosmetic Surgery, highlighting Asian Cosmetic Surgery. He is a member of the American Academy of Cosmetic Surgery, the American Society of Cosmetic Breast Surgery, as well as a member of the California Academy of Cosmetic Surgery. Dr. Napolez has published articles in 5 different Medical Journals, as well as a chapter Author in a textbook on Asian Facial Cosmetic Surgery. He has twice been selected as one of America‚Äôs Top Surgeons in Cosmetic Surgery, as well as a Top Doctor in Plastic Surgery Practice Magazine. Dr. Napolez presented at the 6th 5CC and is scheduled to speak later this year in Manchester, United Kingdom, and Toronto, Canada.


Market Analysis

Skin diseases are probably the most well-known type of problem in the world, with approximately 33% of Americans suffering from what looks like a dynamic skin disease. Much of the dermatology market has been flooded with formulated products for many years. Nevertheless, the clinical and commercial performance of biologics in the treatment of psoriasis and advances in understanding the disease pathways of several skin conditions have generated significant revenue for pharmaceutical companies in the dermatology market, hence the development of the creative pipeline. The global skin disease treatment market was valued at USD 16.4 billion in 2014, or USD 1.7 billion.1 billion USD each in 2015. The market size is expected to reach USD 20.4 billion by 2020 growing at a compound annual growth rate (CAGR) of 3.6% from 2015 to 2022. organ and tissue transplantation items and equipment were $56.9 billion each in 2014.

The market is expected to grow at a compound annual growth rate (CAGR) of 7.1% to reach $64.4 billion in 2015 and nearly $90.6 billion in 2022. The report covers all dermatological concerns, but pays particular attention to three main diseases: atopic dermatitis, dermatitis vulgaris, and psoriasis, as these conditions are the most prevalent and have the largest pipeline. The global dermatology market was estimated at USD 20.0 billion as of 2015 and is projected to grow at a compound annual growth rate (CAGR) of 7.73% to reach USD 33.7 billion as of 2023. Drivers of this development will be higher quality biologics than those previously supported, as well as promising late-stage products that are considered important.